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sources. The NHS perspective was taken and included direct
costs only. In the decision analytical model, patients either
receive MAL-PDT or cryotherapy ﬁrst line with second line
therapy depending on lesion response. A one-year time horizon
was used to capture all relevant resource use and to assess the
clinical response. An excellent cosmetic outcome was deﬁned as
100% complete lesion response, but also no scarring, atrophy or
induration, and no or slight occurrence of redness or change in
pigmentation compared to adjacent skin. Key efﬁcacy data from
the clinical trial were subjected to a stochastic sensitivity analy-
sis using a Beta prior distribution and 1000 simulations.
RESULTS: From the deterministic model, the MAL-PDT strat-
egy dominated cryotherapy. Seventy-three percent of patients
had an excellent cosmetic outcome with MAL-PDT at a cost of
£832.93 per patient compared to 42% of cryotherapy patients
(£843.08 per patient). In the stochastic analysis using 1000 sim-
ulations, 95% of the ICERs were in the range -£161 to £191.
MAL-PDT was the dominant in strategy in 66.3% of the simu-
lations. CONCLUSIONS: MAL-PDT is at least as cost-effective
as cryotherapy in the treatment of thin or non-hyperkeratotic
actinic keratoses (AK) on the face or scalp and has superior cos-
metic outcomes.
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OBJECTIVE: To compare the annual costs of treatment incurred
by a health plan for patients diagnosed with actinic keratosis
(AK) and treated with ﬂuorouracil or cryosurgery. METHODS:
Pharmacy and medical claims from 2.7 million members of a
managed care organization in California, Oklahoma, Oregon,
Texas, and Washington, were examined. Adult patients newly
treated for AK with either 5% ﬂuorouracil cream or cryosurgery,
between January 1 and December 31, 2001, were identiﬁed.
Patients treated with cryosurgery were further stratiﬁed by
number of lesions (i.e., 1, 2–14, >15). Disease-related health care
costs (pharmacy and medical) for a 2-year follow-up period were
evaluated. RESULTS: Of the 9279 identiﬁed patients, 498
(5.4%) were treated with ﬂuorouracil and dermatologists pre-
scribed this medication (48.4%) more often than other special-
ties. Among the 8781 patients treated with cryosurgery, 3004
(34.2%), 5130 (58.4%), and 647 (7.4%) were identiﬁed with 1,
2–14, and >15 lesions, respectively. Total disease-related health
care costs during the follow-up period for the ﬂuorouracil cohort
averaged $509, compared to $296, $523, and $898 for the 1,
2–14, and >15 lesion cohorts, respectively. CONCLUSION: AK
is a common pre-malignant lesion that can develop into squa-
mous cell carcinoma. Numerous options are available for the
treatment of AK, all of which have been shown to be equally
efﬁcacious. In this study, use of 5% ﬂuorouracil cream for the
treatment of multiple AK lesions was cost saving compared to
cryosurgery. Similarly, because ﬂuorouracil is known to treat
sub-clinical lesions, additional savings may be realized for
periods longer than two years.
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The economic burden of psoriasis varies by disease severity.
Moderate to severe psoriasis requires use of systemic treatment
agents and is likely to be associated with higher medical costs.
OBJECTIVE: To estimate health care utilization rates and per-
patient costs for the treatment of moderate to severe psoriasis.
METHODS: A database of health insurance claims from 58 US
commercial health plans was used to obtain patient-level data.
Patients, aged 18–64, included in the analysis had a diagnosis of
psoriasis, and received >1 treatment cycle of at least one of the
following systemic agents: psoralen plus ultraviolet A (PUVA),
methotrexate (Mtx), cyclosporine, acitretin, etretinate, ultravio-
let B (UVB), and systemic corticosteroids (Cs). Patients with <6
months of observation period and those with rheumatoid arthri-
tis and other autoimmune diseases were excluded from the analy-
sis. RESULTS: A total of 1780 patients met all eligibility criteria
noted above (Group 1). Another 282 patients were newly diag-
nosed patients with no prior history of claims for psoriasis (New
Starts; Group 2). The most frequently used systemic therapies by
patients in Group 1, over a period of 1 year, were Cs (42%),
UVB (37%), PUVA (26%), and Mtx (22%). Of patients in
Group 2, 56%, 37%, 31%, and 18% received UVB, Cs, PUVA,
and Mtx. In an analysis of annual per-patient costs for drugs,
outpatient services, and inpatient services, results were compa-
rable for Groups 1 and 2. In Group 1, mean (median) annual
per-patient costs were $917 ($473), $199 ($85), and $6 ($0),
respectively and the corresponding costs for Group 2 were $744
($412), $179 ($63), and $0 ($0), respectively. 90th percentile
annual per-patient costs among all patients and New Starts were
$2932 and $2125, respectively. CONCLUSIONS: Estimates of
annual per-patient costs of treating moderate to severe psoriasis
exceed those reported previously, and reﬂect a considerable
direct medical burden.
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OBJECTIVE: To compare health care expenditures among
patients with dermatophytosis with different predisposing,
enabling and need factors as deﬁned by Andersen-Laake Behav-
ioral Model. METHODS: A cross-sectional analysis of the 1999
Medical Expenditure Panel Survey (MEPS) was conducted.
Patients with dermatophytosis aged 18 years and above were
included in the study. Health care expenditures included costs
related to prescription medications, outpatient, emergency room
and inpatient visits. Predisposing factors included age, gender,
race, education, and marital status. Enabling factors included
insurance type, employment status, family size and income. Need
factors included comorbid conditions, perceived mental and
health status. Analysis of covariance was used to compare the
levels of different factors affecting health care expenditures
adjusting for age. Sampling weights provided by MEPS were
used to provide representative estimates. RESULTS: A total of
156 patients with dermatophytosis were identiﬁed (ICD-9-CM
code = 110.x). These represented 1.8 million patients nationally.
The average age of patients was 51 years. The majority of the
respondents were female (52%); caucasian (87%) had private
insurance (80%) and was married (62%). Health care expendi-
tures for females was signiﬁcantly higher than for males ($831
vs. $450) (p = 0.03). Patients in families with less than three
members spent $232 more than those in families with three or
more members (p = 0.04). Patients with some college education
or higher had higher health care expenditures ($718) compared
with those who had attended high school ($581) or elementary
